Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Ovarian Neoplasms 5Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Radiation Pneumonitis 2Peritoneal Neoplasms 2Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Mesothelioma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophagogastric Adenocarcinoma 1Endometrial Adenocarcinoma 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoid Tumor 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Trastuzumab 243Paclitaxel 193Cyclophosphamide 158Docetaxel 134Letrozole 113Capecitabine 113Fulvestrant 106Doxorubicin 103Bevacizumab 87Carboplatin 81exemestane 80Anastrozole 79Lapatinib 70Tamoxifen 69Albumin-Bound Paclitaxel 57palbociclib 54pertuzumab 53Taxes 51Gemcitabine 50Radiotherapy 46eribulin 43pembrolizumab 41Everolimus 41Ado-Trastuzumab Emtansine 41Vinorelbine 38130-nm albumin-bound paclitaxel 35ixabepilone 32Epirubicin 28pegfilgrastim 25liposomal doxorubicin 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Breast Neoplasms × nintedanib × Clear all
NCT02389764 2019-07-17

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

M.D. Anderson Cancer Center

Phase 2 Terminated
10 enrolled 9 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡